GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using a modified vaccinia ankara virus-like particle vaccine platform. The company is headquartered in Smyrna, Georgia.
| Revenue (TTM) | 852,280 |
| Gross Profit (TTM) | $-15.82M |
| EBITDA | $-21.44M |
| Operating Margin | -2523.00% |
| Return on Equity | -509.00% |
| Return on Assets | -194.60% |
| Revenue/Share (TTM) | $0.64 |
| Book Value | $0.17 |
| Price-to-Book | 13.03 |
| Price-to-Sales (TTM) | 7.09 |
| EV/Revenue | 6.52 |
| EV/EBITDA | 15.26 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $5.21M |
| Float | $3.20M |
| % Insiders | 6.80% |
| % Institutions | 18.28% |
GeoVax Labs (GOVX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
GeoVax Labs, Inc. (GOVX) Discusses Building a Resilient Infectious Disease Preparedness Strategy Focused on Ebola, Marburg, Hantavirus, and Mpox Transcript
GeoVax Labs (GOVX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
